Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood sugar sensitivity may determine heart procedure success

NCT ID NCT07551947

Knowledge-focused Sponsor: Nemocnice AGEL Trinec-Podlesi a.s. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checks if insulin resistance (when your body doesn't use insulin well) can predict whether a heart procedure called pulsed field ablation will work for people with atrial fibrillation (an irregular heartbeat). About 120 non-diabetic patients having their first ablation will give a blood sample before the procedure. Researchers will measure insulin resistance and follow up 4-5 months later to see who needs a repeat procedure. The goal is to find out if treating insulin resistance could improve ablation success.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Non-diabetic adults with atrial fibrillation (paroxysmal or persistent) indicated for first catheter ablation using pulsed field ablation at a single tertiary cardiology center (Cardiocentrum, AGEL Hospital Trinec-Podlesi, Czech Republic).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>= 18 years * Undergoing first catheter ablation for atrial fibrillation using pulsed field ablation (PFA) * No known diagnosis of diabetes mellitus * Signed written informed consent Exclusion Criteria: * Known diabetes mellitus or active antidiabetic treatment * Previous atrial fibrillation ablation by any method * Pregnancy * Severe renal insufficiency (eGFR \< 30 mL/min) * Other severe comorbidities limiting follow-up * Inability to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial intelligence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation Insulin Resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial intelligence Atrial fibrillation Catheter ablation Insulin resistance

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kardiocentrum, Nemocnice AGEL Trinec-Podlesi a.s.

    Třinec, 73961, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.